Patients with dyslipidemia are frequently associated with nonalcoholic fatty liver disease (NAFLD) accompanied by impairment of hepatic functions: elevation of hepatic parameters including AST, ALT, ALP, and γ-GTP [29,30]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.